Literature DB >> 16529552

Mineralocorticoid receptor blockade in the protection of target organ damage.

Paolo Mulatero1, Alberto Milan, Tracy Ann Williams, Franco Veglio.   

Abstract

Over the last decade a wealth of studies have shed new light on the role of aldosterone in the pathogenesis of cardiovascular diseases. It is now evident that in addition to its classical role in increasing sodium re-absorbtion in the kidney , aldosterone also exhibits several nonepithelial effects such as the induction of inflammation, fibrosis and necrosis in various organs. Herein we review the experimental evidences for the protective effects of mineralocorticoid receptor blockade in the prevention and treatment of target organ damage, both in animals and in humans. We also discuss the pharmacological and clinical differences between the two available mineralocorticoid receptor blockers, spironolactone and eplerenone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16529552     DOI: 10.2174/187152506775268776

Source DB:  PubMed          Journal:  Cardiovasc Hematol Agents Med Chem        ISSN: 1871-5257


  7 in total

Review 1.  Diagnosis and treatment of primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Franco Veglio
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

2.  Esaxerenone: First Global Approval.

Authors:  Sean Duggan
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

Review 3.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

4.  Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.

Authors:  Mara Medeiros; Luis Velásquez-Jones; Ana M Hernández; Guillermo Ramón-García; Saúl Valverde; Yolanda Fuentes; Arindal Vargas; Mauricio Patiño; Rosalba Pérez-Villalva; Juan Antonio Ortega-Trejo; Jonatan Barrera-Chimal; Norma A Bobadilla
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-23       Impact factor: 8.237

Review 5.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 6.  Understanding primary aldosteronism: impact of next generation sequencing and expression profiling.

Authors:  Silvia Monticone; Tobias Else; Paolo Mulatero; Tracy A Williams; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2014-09-18       Impact factor: 4.102

7.  Approach to the Patient with Primary Aldosteronism: Utility and Limitations of Adrenal Vein Sampling.

Authors:  Adina F Turcu; Richard Auchus
Journal:  J Clin Endocrinol Metab       Date:  2021-03-25       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.